Chemokines and inflammation in COPD: implications for targeted therapy
DOI:
https://doi.org/10.20883/medical.e1107Keywords:
chemokines, inflammation, targeted therapy, cytokines, pulmonary inflammation, immunomodulation, chronic obstructive pulmonary diseaseAbstract
A severe global health issue, chronic obstructive pulmonary disease (COPD) is characterized by recurrent respiratory symptoms and restricted breathing because of long-term lung inflammation. A class of minuscule cytokines known as chemokines is essential for immune cell recruitment and activation, which sustains the inflammatory response in COPD. This study thoroughly examines the origins, modes of action and effects of chemokines on developing COPD-related inflammation. We detail the involvement of key chemokines, such as CXCL9, CXCL10, and CXCL11, in COPD pathophysiology. These chemokines are integral in attracting neutrophils, macrophages, and T lymphocytes to the lungs, leading to chronic inflammation, airway remodeling, and emphysema. Increased levels of these chemokines correlate with increased disease severity and frequency of exacerbations. The review additionally examines the possibility of using chemokine pathway targeting as a treatment approach. Current COPD treatments primarily address symptoms without adequately controlling underlying inflammation. By inhibiting chemokine signaling, it may be possible to reduce inflammation, slow disease progression, and improve patient outcomes. We discuss various therapeutic approaches, including developing chemokine receptor inhibitors, biologics such as monoclonal antibodies, drug repurposing, and combination therapies with existing treatments. Furthermore, we review ongoing and completed clinical trials investigating chemokine-targeted therapies in COPD, highlighting their efficacy and safety. This review also emphasizes the need for further research to optimize these therapies and identify biomarkers for monitoring treatment response. In conclusion, chemokines are pivotal in the inflammatory processes of COPD. Targeting chemokine pathways presents a promising avenue for developing more effective treatments, potentially significantly enhancing patient care and disease management.
Downloads
References
Liu J, Ran Z, Wang F, Xin C, Xiong B, Song Z. Role of pulmonary microorganisms in the development of chronic obstructive pulmonary disease. Crit Rev Microbiol [Internet]. 2021;47(1):1–12. Available from: http://dx.doi.org/10.1080/1040841x.2020.1830748
Poot CC, Meijer E, Kruis AL, Smidt N, Chavannes NH, Honkoop PJ. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Libr [Internet]. 2021;2021(9). Available from: http://dx.doi.org/10.1002/14651858.cd009437.pub3
D’Anna SE, Maniscalco M, Cappello F, Carone M, Motta A, Balbi B, et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. Ann Med [Internet]. 2021;53(1):135–50. Available from: http://dx.doi.org/10.1080/07853890.2020.1831050
Korbecki J, Grochans S, Gutowska I, Barczak K, Baranowska-Bosiacka I. CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands. Int J Mol Sci [Internet]. 2020;21(20):7619. Available from: http://dx.doi.org/10.3390/ijms21207619
Brandum EP, Jørgensen AS, Rosenkilde MM, Hjortø GM. Dendritic cells and CCR7 expression: An important factor for autoimmune diseases, chronic inflammation, and cancer. Int J Mol Sci [Internet]. 2021;22(15):8340. Available from: http://dx.doi.org/10.3390/ijms22158340
Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther [Internet]. 2022;29(1):10–21. Available from: http://dx.doi.org/10.1038/s41417-021-00303-x
Ghafouri-Fard S, Honarmand K, Taheri M. A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis. Metab Brain Dis [Internet]. 2021;36(3):375–406. Available from: http://dx.doi.org/10.1007/s11011-020-00648-6
Zinellu E, Zinellu A, Fois AG, Pau MC, Scano V, Piras B, et al. Oxidative stress biomarkers in chronic Obstructive Pulmonary Disease exacerbations: A systematic review. Antioxidants (Basel) [Internet]. 2021;10(5):710. Available from: http://dx.doi.org/10.3390/antiox10050710
Korbecki J, Maruszewska A, Bosiacki M, Chlubek D, Baranowska-Bosiacka I. The potential importance of CXCL1 in the physiological state and in noncancer diseases of the cardiovascular system, respiratory system and skin. Int J Mol Sci [Internet]. 2022;24(1):205. Available from: http://dx.doi.org/10.3390/ijms24010205
Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest [Internet]. 2020;158(2):646–59. Available from: http://dx.doi.org/10.1016/j.chest.2020.03.037
Ermakov EA, Mednova IA, Boiko AS, Buneva VN, Ivanova SA. Chemokine dysregulation and neuroinflammation in schizophrenia: A systematic review. Int J Mol Sci [Internet]. 2023;24(3):2215. Available from: http://dx.doi.org/10.3390/ijms24032215
Wu X, Sun M, Yang Z, Lu C, Wang Q, Wang H, et al. The roles of CCR9/CCL25 in inflammation and inflammation-associated diseases. Front Cell Dev Biol [Internet]. 2021;9. Available from: http://dx.doi.org/10.3389/fcell.2021.686548
Ishida Y, Kuninaka Y, Mukaida N, Kondo T. Immune mechanisms of pulmonary fibrosis with bleomycin. Int J Mol Sci [Internet]. 2023;24(4):3149. Available from: http://dx.doi.org/10.3390/ijms24043149
Sulfiana S, Iswanti FC. Chemokines in allergic asthma inflammation. Zinc Suppl Improv Heme Biosynth Rats Expo Lead [Internet]. 2022;41(3):289–301. Available from: http://dx.doi.org/10.18051/univmed.2022.v41.289-301
Zhang S, Li G. Tumor expression of CXCL12 and survival of patients with colorectal cancer: A meta‑analysis. Oncol Lett [Internet]. 2022;24(6). Available from: http://dx.doi.org/10.3892/ol.2022.13556
Satarkar D, Patra C. Evolution, expression and functional analysis of CXCR3 in neuronal and cardiovascular diseases: A narrative review. Front Cell Dev Biol [Internet]. 2022;10. Available from: http://dx.doi.org/10.3389/fcell.2022.882017
Karnati S, Seimetz M, Kleefeldt F, Sonawane A, Madhusudhan T, Bachhuka A, et al. Chronic obstructive pulmonary disease and the cardiovascular system: Vascular repair and regeneration as a therapeutic target. Front Cardiovasc Med [Internet]. 2021;8. Available from: http://dx.doi.org/10.3389/fcvm.2021.649512
Cendrowicz E, Sas Z, Bremer E, Rygiel TP. The role of macrophages in cancer development and therapy. Cancers (Basel) [Internet]. 2021;13(8):1946. Available from: http://dx.doi.org/10.3390/cancers13081946
Dey S, Eapen MS, Chia C, Gaikwad AV, Wark PAB, Sohal SS. Pathogenesis, clinical features of asthma COPD overlap, and therapeutic modalities. Am J Physiol Lung Cell Mol Physiol [Internet]. 2022;322(1):L64–83. Available from: http://dx.doi.org/10.1152/ajplung.00121.2021
Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med [Internet]. 2021;203(1):24–36. Available from: http://dx.doi.org/10.1164/rccm.202009-3533so
Ham J, Kim J, Ko YG, Kim HY. The dynamic contribution of neutrophils in the chronic respiratory diseases. Allergy Asthma Immunol Res [Internet]. 2022;14(4):361. Available from: http://dx.doi.org/10.4168/aair.2022.14.4.361
Dailah HG. Therapeutic potential of small molecules targeting oxidative stress in the treatment of chronic obstructive pulmonary disease (COPD): A comprehensive review. Molecules [Internet]. 2022;27(17):5542. Available from: http://dx.doi.org/10.3390/molecules27175542
Mishra RK, Ahmad A, Vyawahare A, Kumar A, Khan R. Understanding the monoclonal antibody involvement in targeting the activation of tumor suppressor genes. Curr Top Med Chem [Internet]. 2020;20(20):1810–23. Available from: http://dx.doi.org/10.2174/1568026620666200616133814
Zhou C, Gao Y, Ding P, Wu T, Ji G. The role of CXCL family members in different diseases. Cell Death Discov [Internet]. 2023;9(1). Available from: http://dx.doi.org/10.1038/s41420-023-01524-9
Calzetta L, Coppola A, Ritondo BL, Matino M, Chetta A, Rogliani P. The impact of muscarinic receptor antagonists on airway inflammation: A systematic review. Int J Chron Obstruct Pulmon Dis [Internet]. 2021;16:257–79. Available from: http://dx.doi.org/10.2147/copd.s285867
Moradi S, Jarrahi E, Ahmadi A, Salimian J, Karimi M, Zarei A, et al. PI3K signalling in chronic obstructive pulmonary disease and opportunities for therapy. J Pathol [Internet]. 2021;254(5):505–18. Available from: http://dx.doi.org/10.1002/path.5696
Goonathilake MR, Waqar S, George S, Jean-Baptiste W, Yusuf Ali A, Inyang B, et al. Can phosphodiesterase 4 inhibitor therapy be used in respiratory diseases other than chronic obstructive pulmonary disease? Cureus [Internet]. 2022; Available from: http://dx.doi.org/10.7759/cureus.27132
Feng L, Lv X, Wang Y, Chu S, Dai Z, Jing H, et al. Developments in smoking cessation interventions for patients with chronic obstructive pulmonary disease in the past 5 years: a scoping review. Expert Rev Respir Med [Internet]. 2022;16(7):749–64. Available from: http://dx.doi.org/10.1080/17476348.2022.2108797
Budnevsky AV, Avdeev SN, Ovsyannikov ES, Savushkina IA, Shkatova YS, Shishkina VV. The role of mast cells in the pathogenesis of chronic obstructive pulmonary disease. Russ Pulmonol [Internet]. 2022;34(1):65–73. Available from: http://dx.doi.org/10.18093/0869-0189-2022-3504
Peng J, Yu Q, Fan S, Chen X, Tang R, Wang D, et al. High blood eosinophil and YKL-40 levels, as well as low CXCL9 levels, are associated with increased readmission in patients with acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis [Internet]. 2021;16:795–806. Available from: http://dx.doi.org/10.2147/copd.s294968
Zhang W, Wang H, Sun M, Deng X, Wu X, Ma Y, et al. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun (Lond) [Internet]. 2020;40(2–3):69–80. Available from: http://dx.doi.org/10.1002/cac2.12010
Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 axis in cancer progression. Cancers (Basel) [Internet]. 2020;12(7):1765. Available from: http://dx.doi.org/10.3390/cancers12071765
Files DC, Tacke F, O’Sullivan A, Dorr P, Ferguson WG, Powderly WG. Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. PLoS Pathog [Internet]. 2022;18(6):e1010547. Available from: http://dx.doi.org/10.1371/journal.ppat.1010547
Mehta PP, Dhapte-Pawar VS. Repurposing drug molecules for new pulmonary therapeutic interventions. Drug Deliv Transl Res [Internet]. 2021;11(5):1829–48. Available from: http://dx.doi.org/10.1007/s13346-020-00874-6
Bhat A, Ray B, Mahalakshmi AM, Tuladhar S, Nandakumar DN, Srinivasan M, et al. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Pharmacol Res [Internet]. 2020;160(105078):105078. Available from: http://dx.doi.org/10.1016/j.phrs.2020.105078
Nomani H, Mohammadpour AH, Reiner Ž, Jamialahmadi T, Sahebkar A. Statin therapy in post-operative atrial fibrillation: Focus on the anti-inflammatory effects. J Cardiovasc Dev Dis [Internet]. 2021;8(3):24. Available from: http://dx.doi.org/10.3390/jcdd8030024
Heidary M, Ebrahimi Samangani A, Kargari A, Kiani Nejad A, Yashmi I, Motahar M, et al. Mechanism of action, resistance, synergism, and clinical implications of azithromycin. J Clin Lab Anal [Internet]. 2022;36(6). Available from: http://dx.doi.org/10.1002/jcla.24427
Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy [Internet]. 2020;75(5):1023–42. Available from: http://dx.doi.org/10.1111/all.14221
Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med [Internet]. 2020;201(9):e56–69. Available from: http://dx.doi.org/10.1164/rccm.202003-0625st
Hurst JR, Gruffydd-Jones K, Biswas M, Guranlioglu D, Jenkins M, Stjepanovic N, et al. Efficacy and safety of LAMA/LABA fixed-dose combination therapies in chronic obstructive pulmonary disease: A systematic review of direct and indirect treatment comparisons. Int J Chron Obstruct Pulmon Dis [Internet]. 2020;15:1529–43. Available from: http://dx.doi.org/10.2147/copd.s230955
Calzetta L, Aiello M, Frizzelli A, Bertorelli G, Ritondo BL, Rogliani P, et al. The impact of monoclonal antibodies on airway smooth muscle contractility in asthma: A systematic review. Biomedicines [Internet]. 2021;9(9):1281. Available from: http://dx.doi.org/10.3390/biomedicines9091281
Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol [Internet]. 2020;17(12):725–41. Available from: http://dx.doi.org/10.1038/s41571-020-0413-z
Tashkin DP, Amin AN, Kerwin EM. Comparing randomized controlled trials and real-world studies in chronic obstructive pulmonary disease pharmacotherapy. Int J Chron Obstruct Pulmon Dis [Internet]. 2020;15:1225–43. Available from: http://dx.doi.org/10.2147/copd.s244942
Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, et al. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res [Internet]. 2020;21(1). Available from: http://dx.doi.org/10.1186/s12931-020-01482-1
Martin C, Burgel P-R, Roche N. Inhaled dual phosphodiesterase 3/4 inhibitors for the treatment of patients with COPD: A short review. Int J Chron Obstruct Pulmon Dis [Internet]. 2021;16:2363–73. Available from: http://dx.doi.org/10.2147/copd.s226688
Martinez FJ, Agusti A, Celli BR, Han MK, Allinson JP, Bhatt SP, et al. Treatment trials in young patients with chronic obstructive pulmonary disease and pre–chronic obstructive pulmonary disease patients: Time to move forward. Am J Respir Crit Care Med [Internet]. 2022;205(3):275–87. Available from: http://dx.doi.org/10.1164/rccm.202107-1663so
Zhen G, Yingying L, Jingcheng D. Drug therapies for COPD: A bibliometric review from 1980 to 2021. Front Pharmacol [Internet]. 2022;13. Available from: http://dx.doi.org/10.3389/fphar.2022.820086
Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of chronic obstructive pulmonary disease (COPD): A systematic literature review. Int J Chron Obstruct Pulmon Dis [Internet]. 2020;15:439–60. Available from: http://dx.doi.org/10.2147/copd.s234942
Che Man R, Sulaiman N, Ishak MF, Bt Hj Idrus R, Abdul Rahman MR, Yazid MD. The effects of pro-inflammatory and anti-inflammatory agents for the suppression of intimal hyperplasia: An evidence-based review. Int J Environ Res Public Health [Internet]. 2020;17(21):7825. Available from: http://dx.doi.org/10.3390/ijerph17217825
Budnevsky AV, Avdeev SN, Ovsyannikov ES, Savushkina IA, Shkatova YS, Shishkina VV. The role of mast cells in the pathogenesis of chronic obstructive pulmonary disease. Russ Pulmonol [Internet]. 2022;34(1):65–73. Available from: http://dx.doi.org/10.18093/0869-0189-2022-3504
Conlon T, John-Schuster G, Günes G, Jeridi A, Ertüz Z, Lehmann M, et al. Therapeutic targeting of iBALT induces lung regeneration in COPD. In: 0303 - Mechanisms of lung injury and repair. European Respiratory Society; 2021. p. 83.
Keir HR, Richardson H, Fillmore C, Shoemark A, Lazaar AL, Miller BE, et al. CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin. ERJ Open Res [Internet]. 2020;6(4):00583–2020. Available from: http://dx.doi.org/10.1183/23120541.00583-2020
Kameda M, Otsuka M, Chiba H, Kuronuma K, Hasegawa T, Takahashi H, et al. CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases–associated interstitial lung disease and interstitial pneumonia with autoimmune features. PLoS One [Internet]. 2020;15(11):e0241719. Available from: http://dx.doi.org/10.1371/journal.pone.0241719
Published
Issue
Section
License
Copyright (c) 2025 The copyright to the submitted manuscript is held by the Author, who grants the Journal of Medical Science (JMS) a nonexclusive licence to use, reproduce, and distribute the work, including for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
